S1 Biopharma is a developer of first-in-class drugs for sexual dysfunction in both women and men. The company's lead compound, Lorexys, is currently in Phase IIb for the treatment of hypoactive sexual ...

In exclusive interviews, the filmmakers behind 'The Pink Pill' documentary share how they brought the fight for FDA approval ...

Credit: Sprout Pharmaceuticals The approval was based on a randomized, double-blind, placebo-controlled phase 3 trial, which included 447 postmenopausal women with acquired, generalized HSDD.

In the often unspoken world of female sexual health, a revolution has started, and it began with the introduction of a unique medication called Addyi. Traditionally, when we think of sexual ...

The FDA has expanded its approval of a libido-boosting drug to postmenopausal women. Xvision/Getty Images Postmenopause refers to the time period after the person finishes menopause and no longer has ...

The US Food and Drug Administration (FDA) today approved bremelanotide (Vyleesi, AMAG Pharmaceuticals), a first-in-class melanocortin 4 receptor agonist for hypoactive sexual desire disorder (HSDD) in ...

Sprout Pharmaceuticals, Inc. (Sprout), a division of Valeant Pharmaceuticals North America LLC, announced today that Addyi, a once-daily, non-hormonal pill for the treatment of acquired, generalized ...

Only FDA-Approved As-Needed Treatment For The Approximately 6 Million Premenopausal Women Who Suffer From Hypoactive Sexual Desire Disorder (HSDD) Vyleesi® has experienced 8 Consecutive Quarters of ...

(StatePoint) Forty-two percent of women experience sexual dysfunction — and Hypoactive Sexual Desire Disorder (HSDD) — characterized as frustrating low libido, is the most common form of it. It is ...

Add Yahoo as a preferred source to see more of our stories on Google. “Typically, women with HSDD report that they have no interest in having sex, either solo or with a partner, and it bothers them,” ...